Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
Adaptive Biotechnologies Co. (NASDAQ: ADPT) had its price target lowered by analysts at BTIG Research from $6.00 to $5.00. They now have a "buy" rating on the stock.
Adaptive Biotechnologies announces conclusion of strategic review, expects Q1 revenue between $41M and $43M [Seeking Alpha]
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue [Yahoo! Finance]
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue